DUBLIN, Ireland, April 9, 2026
Jazz Pharmaceuticals plc has announced the presentation of six scientific abstracts, including one oral presentation, at the 2026 American Academy of Neurology (AAN) Annual Meeting, highlighting new clinical and real-world evidence for its key therapies Epidiolex® (cannabidiol) and Xywav® (low-sodium oxybate). The data underscore the company’s continued commitment to addressing rare neurological disorders, including epilepsy and sleep disorders, through innovative research and patient-focused drug development.
New Clinical Data Highlights Efficacy in Epilepsy Treatment
Among the key highlights is an oral presentation from the Phase 3b/4 EpiCom study, demonstrating that treatment with Epidiolex® resulted in significant reductions in behavioral symptoms associated with tuberous sclerosis complex (TSC) after 26 weeks. Improvements were observed across multiple validated clinical scales, including caregiver-reported and clinician-reported outcomes, reinforcing the drug’s potential to address both seizure control and neuropsychiatric symptoms.
Additional analyses involving over 7,800 patients provided insights into treatment persistence and real-world usage patterns, identifying critical factors influencing long-term adherence to cannabidiol therapy. These findings are particularly important in managing complex and treatment-resistant epilepsies, where maintaining consistent therapy is essential for achieving optimal outcomes. The breadth of data reflects a strong focus on real-world evidence (RWE), which is increasingly important in understanding the full patient journey and treatment impact beyond controlled clinical trials.
Xywav Research Demonstrates Improvements in Narcolepsy Outcomes
Advertisement
Jazz also presented new findings from the DUET study, evaluating Xywav®, the only low-sodium oxybate therapy approved by the FDA for narcolepsy and idiopathic hypersomnia. The study demonstrated that patients receiving optimized higher doses (>9 grams per night) experienced significant improvements in cognitive function, daily activities, work productivity, and overall disease burden compared to standard dosing levels.
These results highlight the importance of dose optimization in managing sleep disorders, where personalized treatment approaches can lead to enhanced quality of life and functional outcomes. Notably, Xywav’s formulation delivers 92% less sodium compared to traditional oxybate therapies, addressing long-term cardiovascular safety concerns associated with high sodium intake. This innovation represents a meaningful advancement in sleep medicine, offering patients a safer and more effective therapeutic option.
Advancing Biopharma Innovation Through Real-World Evidence
The research presented at the AAN Annual Meeting reflects Jazz Pharmaceuticals’ broader strategy of integrating clinical trial data with real-world evidence to improve treatment strategies and patient outcomes. By focusing on rare and complex neurological conditions, the company aims to address significant unmet medical needs through continuous innovation and lifecycle management of approved therapies.
From a cGxP perspective, these studies highlight the importance of Good Clinical Practice (GCP) in generating reliable data, as well as the role of post-marketing research and pharmacovigilance in ensuring long-term drug safety and effectiveness. The integration of large-scale patient data, observational studies, and clinical trial findings demonstrates how modern pharmaceutical companies are leveraging data-driven insights to refine treatment approaches and support regulatory and clinical decision-making.
The company’s participation in a major global scientific congress such as AAN also underscores the importance of scientific exchange and evidence dissemination in advancing the field of neurology and improving patient care standards worldwide.
The presentation of new data by Jazz Pharmaceuticals at the 2026 AAN Annual Meeting marks a significant step in advancing the understanding and treatment of epilepsy and sleep disorders, reinforcing the value of real-world evidence and clinical research in modern biopharma. By demonstrating improved patient outcomes, enhanced treatment strategies, and ongoing innovation, the company continues to strengthen its position as a leader in rare neurological disease therapeutics, contributing to the development of more effective and patient-centered healthcare solutions.
Source: Jazz Pharmaceuticals press release
